{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:02:28Z","timestamp":1778832148547,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.breast.2016.08.015","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T08:15:36Z","timestamp":1473840936000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France"],"prefix":"10.1016","volume":"30","author":[{"given":"Aline","family":"Hurtaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Donnadieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Escalup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Baffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2016.08.015_bib1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the European Union: a population-based cost analysis","volume":"14","author":"Luengo-Fernandez","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","article-title":"Delivering affordable cancer care in high-income countries","volume":"12","author":"Sullivan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.breast.2012.03.012","article-title":"Metastatic breast cancer: we do need primary cost data","volume":"21","author":"Bonastre","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.breast.2016.08.015_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/annonc\/mdm491","article-title":"Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival","volume":"19","author":"Dabakuyo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.2015.127","article-title":"Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?","volume":"112","author":"Lobbezoo","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib6","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)\u2020","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib7","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2217\/fon.15.80","article-title":"Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer","volume":"11","author":"Jerusalem","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2016.08.015_bib9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155214525369","article-title":"A\u00a0comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting","volume":"21","author":"Dranitsaris","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.breast.2016.08.015_bib11","first-page":"320","article-title":"Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study","volume":"5","author":"Gamucci","year":"2014","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3109\/0284186X.2014.973063","article-title":"A\u00a0retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden","volume":"54","author":"Kessler","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bulcan.2015.03.021","article-title":"Efficacy, safety and cost of eribulin in patients with metastatic breast cancer","volume":"102","author":"Paillard","year":"2015","journal-title":"Bull Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/fon.13.251","article-title":"Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital","volume":"10","author":"Poletti","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2016.08.015_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-012-2326-8","article-title":"A\u00a0cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer","volume":"137","author":"Lopes","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2016.08.015_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40273-014-0214-2","article-title":"Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal","volume":"33","author":"Greenhalgh","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2016.08.015_bib18","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1200\/JCO.2014.55.8437","article-title":"Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis","volume":"32","author":"Niraula","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/1472-6963-13-456","article-title":"Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study","volume":"13","author":"Baffert","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.breast.2016.08.015_bib20","first-page":"493","article-title":"Burden of breast cancer with brain metastasis: a French national hospital database analysis","volume":"15","author":"Benjamin","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.breast.2016.08.015_bib21","first-page":"929","article-title":"Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region","volume":"96","author":"Trombert Paviot","year":"2009","journal-title":"Bull Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S0266462307070328","article-title":"Resource use and costs associated with different states of breast cancer","volume":"23","author":"Lidgren","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.breast.2016.08.015_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10549-012-2097-2","article-title":"The economic burden of metastatic breast cancer: a U.S. managed care perspective","volume":"134","author":"Montero","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2016.08.015_bib24","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2013.51.0651","article-title":"Delivering high-quality and affordable care throughout the cancer care continuum","volume":"31","author":"Shih","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib25","first-page":"585","article-title":"Advanced breast cancer: an evaluation of the cost of recurrence","volume":"86","author":"Bercez","year":"1999","journal-title":"Bull Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/bjc.1992.91","article-title":"The cost of breast cancer recurrences","volume":"65","author":"Hurley","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2407-11-250","article-title":"Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality","volume":"11","author":"Vera-Llonch","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2016.08.015_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-010-1311-3","article-title":"Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994\u20131998 and 2003\u20132006","volume":"128","author":"Galy","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2016.08.015_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1200\/JCO.2015.64.7867","article-title":"The value of considering cost, and the cost of not considering value","volume":"34","author":"Saltz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2016.08.015_bib32","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","article-title":"Pooled analyses of eribulin in metastatic breast cancer patients with at least 1 prior chemotherapy","volume":"27","author":"Pivot","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2016.08.015_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.2013-0282","article-title":"Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer","volume":"19","author":"Muss","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2016.08.015_bib34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1634\/theoncologist.2015-0002","article-title":"Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?","volume":"20","author":"Bonotto","year":"2015","journal-title":"Oncologist"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616301588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977616301588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:35:45Z","timestamp":1760776545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977616301588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":34,"alternative-id":["S0960977616301588"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2016.08.015","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2016.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}